肿瘤患者支持/姑息治疗是一项涉及范围广泛、整体、全方位的诊疗体系；成功的支持/姑息治疗贯穿于疾病诊断、治疗、终末期全程，以及癌症生存者（包括治疗和康复者）管理等；其在疾病不同阶段目标不同。支持/姑息治疗目的是提高肿瘤患者生活质量，帮助患者及家属面对与威胁生命疾病相关的各种问题。中国医疗保健国际交流促进会肿瘤姑息治疗与人文关怀分会（CAHPC）成立于2015年，其团结在CRPC周围，旨在建立姑息理念传播平台、促进学术交流和研究合作、推动支持/姑息治疗与医学人文在国内的发展。CAHPC本次很荣幸再度与【肿瘤资讯】携手启航，共邀20余位专家和优秀中青年医师为大家奉献2018年ASCO在支持/姑息治疗的相关精彩研究进展！

下面我们带大家抢先了解即将在ASCO 2018年会发布的有关支持/姑息治疗最新研究。目前支持/姑息领域共遴选出254篇摘要，涉及13个专题，大体简单分为“身、心、社”及支持/姑息治疗模式探讨四大板块。

一：“身”部分，包括肿瘤相关症状例如疲乏、疼痛、CINV、神经毒性、免疫治疗相关毒性等；临终关怀等  

二：“心”部分，包括肿瘤相关心理症状例如化疗后认知功能障碍、抑郁焦虑干预等；医患沟通的相关研究。

三：“社”部分，包括了有关癌症照顾者、癌症生存者多项研究；健康的生活方式的相关研究。

四：支持/姑息治疗模式探讨，有关肿瘤护理进展，远程医疗、医疗经济学、PRO等热点应用等问题。

大会特开设支持/姑息治疗专场，为我们带来关于症状控制、患者生活质量、医疗模式探讨等多方面的研究新进展。

摘要10004：Symptom burden in hospitalized patients with curable and incurable cancers

摘要10005：Randomized trial of a symptom monitoring intervention for hospitalized patients with cancer. 

摘要10007：Patient (Pt) and oncologist (MD) discordance in goals of care in end of life (EOL) decision making.

摘要10109：Patient-defined goals and preferences among older adults with cancer starting chemotherapy (CT).

摘要10010：Quality of life (QoL) in older patients (pts) with cancer and prognostic factors for QoL decline

摘要10016：Scrambler therapy for established chemotherapy-induced neuropathy: A randomized phase II trial。

摘要10017：Randomized, double-blind, phase III trial of monosialotetrahexosylganglioside versus placebo in GI cancer patients with oxaliplatin induced peripheral

摘要10018：Pretreatment physical activity to predict short- and long-term chemotherapy-induced peripheral neuropathy (CIPN) in a nationwide longitudinal study of paclitaxel for breast cancer.

摘要10019： Efficacy and safety of additional olanzapine to ondansetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting: A randomized, double-blind, placebo-controlled, crossover study.

摘要1078： Efficacy of mirtazapine in preventing delayed nausea and vomiting induced by highly emetogenic chemotherapy: An open-label, randomized, multicenter phase III trial.

摘要10527：Intravenous fosaprepitant for the prevention of chemotherapy induced vomiting in children: A double blind placebo controlled, phase III randomized trial.

摘要10053：Efficacy of haloperidol versus olanzapine for control of chemotherapy induced nausea and vomiting.

摘要10112：The impact of pain in recurrent ovarian cancer patients: An individual participant data meta-analysis of the North-Eastern German Society of Gynecological Oncology (NOGGO) of 1226 patients.

摘要10102：A multi-center, randomized, double-blinded, placebo-controlled trial of additive effect of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: JORTC- PAL08 (DIRECT study).

摘要6602：A nationwide analysis of palliative care service utilization in hospitalized

摘要10118：Efficacy of omega-3 (v3) supplementation versus omega-6 (v6) supplementation for reducing pain among breast cancer survivors:

A URCC NCORP RCT metastatic cancer patients.

摘要6538：Efficacy of omega-3 (v3) supplementation versus omega-6 (v6) supplementation for reducing pain among breast cancer survivors:

A URCC NCORP RCT metastatic cancer patients.

摘要10057：Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated thrombosis

摘要10091：PG2 injection, a novel botanical drug approved for improving cancer-related fatigue among advanced cancer patients under standard palliative care: A double blind, multi-center, randomized phase IV study.

摘要10061： longitudinal assessment to evaluate the impact of higher body mass index on cancer-related fatigue in breast cancer patients receiving chemotherapy.

摘要10101：Risk stratification using patient-reported outcomes (PROs) in patients (pts) with advanced cancer. 

2018年ASCO会议主题“Delivering Discoverise:Expanding The Reach Of  Precision Medicine” “传递发现：扩展精准医学领域”。会议内容涵盖了癌症预防和治疗多个方面，从精准医学到癌症生存者的康复等涉及多方面内容。其中支持/姑息治疗成为大家关注的热点领域，相信ASCO开幕后将有更多的精彩内容呈现。

“CAHPC姑息情报局”专栏在CAHPC主任委员北京大学肿瘤医院姑息治疗中心主任刘巍教授积极倡导下，继“肿瘤姑息漫步学社”后的又一杰作。“情报局”一经推出就备受业界关注和认可，2017年累计阅读次数达千次。2018年将再接再厉，我们CAHPC团队将携手【肿瘤资讯】带来更多精彩内容，请您继续关注“CAHPC带您走进ASCO 2018”系列报道。